Glaxo Mckesson: A Deal Or Just Talk?
Drugmaker Glaxo is after McKesson's PCS pharmacy-benefits-management unit. But its game plan is unclear. In two days, McKesson stock soared 12%, to 807 8 on May 10, on a report that Glaxo was negotiating to buy the division. It fell the next day on talk that the companies simply would sign a strategic agreement. Neither side would comment, but a deal wouldn't be much of a surprise: Drugmakers want benefits managers such as PCS to ensure that their brands are chosen among equivalent drugs. That's why Merck bought Medco, and why SmithKline is buying DPS.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.